Amneal Launches Brekiya®, First Ready-to-Use DHE Autoinjector For Migraine And Cluster Headache

Amneal Pharmaceuticals, Inc. has announced the U.S. commercial launch of Brekiya® (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and cluster headaches in adults. Brekiya offers a convenient, self-administered option for patients and is available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.

“We are excited to introduce Brekiya autoinjector, making this innovative therapy broadly available to healthcare providers and patients. As the first and only self-administered, ready-to-use DHE autoinjector, Brekiya offers patients the ability to treat debilitating attacks in a convenient way and avoid visits to the emergency room. With our expanding neurology portfolio, Amneal is committed to supporting providers through comprehensive education and ensuring strong patient access as we bring Brekiya autoinjector to market,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.

Migraine affects nearly 43 million Americans, and around 300,000 individuals experience cluster headaches—conditions that are both painful and underserved in terms of treatment options. Headache disorders also account for approximately 3% of U.S. emergency department visits, highlighting the need for more accessible therapies. Brekiya provides a new, fast-acting treatment choice for adults who suffer from these debilitating headaches.

Brekiya will be available by prescription only, with eligible commercially insured patients paying as little as $40 per carton (which includes four single-dose autoinjectors). Amneal will also provide field reimbursement specialists to help healthcare providers with access, coverage, and reimbursement support. Patients are advised not to take Brekiya with strong CYP3A4 inhibitors such as protease inhibitors or macrolide antibiotics. The medication is indicated only for acute migraine and cluster headache attacks and is not approved for prevention or for use in children.